Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 120 entries
Sorted by: Best Match Show Resources per page
Eosinophilic fasciitis after parasite infection.

Reumatologia

Oliveira M, Patinha F, Marinho A.
PMID: 27407276
Reumatologia. 2016;54(1):38-41. doi: 10.5114/reum.2016.58761. Epub 2016 Mar 24.

Eosinophilic fasciitis is a systemic inflammatory disease characterized by symmetrical swelling and skin induration of the distal portions of the arms and/or legs, evolving into a scleroderma-like appearance, accompanied by peripheral blood eosinophilia. It is a rare disease with...

Cite
Oliveira M, Patinha F, Marinho A. Eosinophilic fasciitis after parasite infection. Reumatologia. 2016;54(1):38-41doi: 10.5114/reum.2016.58761.
Oliveira, M., Patinha, F., & Marinho, A. (2016). Eosinophilic fasciitis after parasite infection. Reumatologia, 54(1), 38-41. https://doi.org/10.5114/reum.2016.58761
Oliveira, Marta, et al. "Eosinophilic fasciitis after parasite infection." Reumatologia vol. 54,1 (2016): 38-41. doi: https://doi.org/10.5114/reum.2016.58761
Oliveira M, Patinha F, Marinho A. Eosinophilic fasciitis after parasite infection. Reumatologia. 2016;54(1):38-41. doi: 10.5114/reum.2016.58761. Epub 2016 Mar 24. PMID: 27407276; PMCID: PMC4847322.
Copy Download .nbib Format: NLM
Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.

Rheumatology and therapy

Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M.
PMID: 30370468
Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28.

INTRODUCTION: This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).METHODS: This was a 12-month noninterventional, observational study in adult patients with RA who...

Cite
Haraoui B, Jamal S, Ahluwalia V, et al. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatol Ther. 2018;5(2):551-565doi: 10.1007/s40744-018-0130-6.
Haraoui, B., Jamal, S., Ahluwalia, V., Fung, D., Manchanda, T., & Khraishi, M. (2018). Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatology and therapy, 5(2), 551-565. https://doi.org/10.1007/s40744-018-0130-6
Haraoui, Boulos, et al. "Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study." Rheumatology and therapy vol. 5,2 (2018): 551-565. doi: https://doi.org/10.1007/s40744-018-0130-6
Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28. PMID: 30370468; PMCID: PMC6251854.
Copy Download .nbib Format: NLM
Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort.

Annals of the rheumatic diseases

Costa L, Tasso M, Scotti N, Mostacciuolo E, Girolimetto N, Foglia F, Del Puente A, Scarpa R, Caso F.
PMID: 32527866
Ann Rheum Dis. 2020 Jun 11; doi: 10.1136/annrheumdis-2020-217806. Epub 2020 Jun 11.

No abstract available.

Cite
Costa L, Tasso M, Scotti N, et al. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-217806.
Costa, L., Tasso, M., Scotti, N., Mostacciuolo, E., Girolimetto, N., Foglia, F., Del Puente, A., Scarpa, R., & Caso, F. (2020). Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-217806
Costa, Luisa, et al. "Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-217806
Costa L, Tasso M, Scotti N, Mostacciuolo E, Girolimetto N, Foglia F, Del Puente A, Scarpa R, Caso F. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Ann Rheum Dis. 2020 Jun 11; doi: 10.1136/annrheumdis-2020-217806. Epub 2020 Jun 11. PMID: 32527866.
Copy Download .nbib Format: NLM
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .

Annals of the rheumatic diseases

D'Silva KM, Serling-Boyd N, Wallwork R, Hsu TY, Sparks JA, Wallace ZS.
PMID: 32660976
Ann Rheum Dis. 2020 Jul 13; doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.

No abstract available.

Cite
D'Silva KM, Serling-Boyd N, Wallwork R, et al. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218431.
D'Silva, K. M., Serling-Boyd, N., Wallwork, R., Hsu, T. Y., Sparks, J. A., & Wallace, Z. S. (2020). Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218431
D'Silva, Kristin M, et al. "Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218431
D'Silva KM, Serling-Boyd N, Wallwork R, Hsu TY, Sparks JA, Wallace ZS. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques . Ann Rheum Dis. 2020 Jul 13; doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13. PMID: 32660976.
Copy Download .nbib Format: NLM
Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M .

Annals of the rheumatic diseases

Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J.
PMID: 32732243
Ann Rheum Dis. 2020 Jul 30; doi: 10.1136/annrheumdis-2020-218609. Epub 2020 Jul 30.

No abstract available.

Cite
Andreica I, Kiefer D, Rezniczek GA, et al. Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218609.
Andreica, I., Kiefer, D., Rezniczek, G. A., Jast, R., Buehring, B., Kiltz, U., Baraliakos, X., & Braun, J. (2020). Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218609
Andreica, Ioana, et al. "Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218609
Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J. Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . Ann Rheum Dis. 2020 Jul 30; doi: 10.1136/annrheumdis-2020-218609. Epub 2020 Jul 30. PMID: 32732243.
Copy Download .nbib Format: NLM
Should patients starting biologics be screened for COVID-19?.

Annals of the rheumatic diseases

Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA.
PMID: 32632031
Ann Rheum Dis. 2020 Jul 06; doi: 10.1136/annrheumdis-2020-218437. Epub 2020 Jul 06.

No abstract available.

Cite
Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Should patients starting biologics be screened for COVID-19?. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218437.
Cardenas-de la Garza, J. A., Arvizu-Rivera, R. I., & Galarza-Delgado, D. A. (2020). Should patients starting biologics be screened for COVID-19?. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218437
Cardenas-de la Garza, Jesus Alberto, et al. "Should patients starting biologics be screened for COVID-19?." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218437
Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Should patients starting biologics be screened for COVID-19?. Ann Rheum Dis. 2020 Jul 06; doi: 10.1136/annrheumdis-2020-218437. Epub 2020 Jul 06. PMID: 32632031.
Copy Download .nbib Format: NLM
Riociguat in systemic sclerosis: a potential for disease modification.

Annals of the rheumatic diseases

Jain S, Dhir V.
PMID: 32669302
Ann Rheum Dis. 2020 Jul 15; doi: 10.1136/annrheumdis-2020-218180. Epub 2020 Jul 15.

No abstract available.

Cite
Jain S, Dhir V. Riociguat in systemic sclerosis: a potential for disease modification. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218180.
Jain, S., & Dhir, V. (2020). Riociguat in systemic sclerosis: a potential for disease modification. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218180
Jain, Siddharth, and Dhir, Varun. "Riociguat in systemic sclerosis: a potential for disease modification." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218180
Jain S, Dhir V. Riociguat in systemic sclerosis: a potential for disease modification. Ann Rheum Dis. 2020 Jul 15; doi: 10.1136/annrheumdis-2020-218180. Epub 2020 Jul 15. PMID: 32669302.
Copy Download .nbib Format: NLM
Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks .

Annals of the rheumatic diseases

Wallace ZS, Sparks JA, Robinson PC, Machado PM, Yazdany J.
PMID: 34426400
Ann Rheum Dis. 2021 Aug 23; doi: 10.1136/annrheumdis-2021-220960. Epub 2021 Aug 23.

No abstract available.

Cite
Wallace ZS, Sparks JA, Robinson PC, et al. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks . Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-220960.
Wallace, Z. S., Sparks, J. A., Robinson, P. C., Machado, P. M., & Yazdany, J. (2021). Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-220960
Wallace, Zachary S, et al. "Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks ." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-220960
Wallace ZS, Sparks JA, Robinson PC, Machado PM, Yazdany J. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks . Ann Rheum Dis. 2021 Aug 23; doi: 10.1136/annrheumdis-2021-220960. Epub 2021 Aug 23. PMID: 34426400.
Copy Download .nbib Format: NLM
Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal.

Science advances

Svensson MND, Zoccheddu M, Yang S, Nygaard G, Secchi C, Doody KM, Slowikowski K, Mizoguchi F, Humby F, Hands R, Santelli E, Sacchetti C, Wakabayashi K, Wu DJ, Barback C, Ai R, Wang W, Sims GP, Mydel P, Kasama T, Boyle DL, Galimi F, Vera D, Tremblay ML, Raychaudhuri S, Brenner MB, Firestein GS, Pitzalis C, Ekwall AH, Stanford SM, Bottini N.
PMID: 32637608
Sci Adv. 2020 Jun 26;6(26):eaba4353. doi: 10.1126/sciadv.aba4353. eCollection 2020 Jun.

Fibroblast-like synoviocytes (FLS) are joint-lining cells that promote rheumatoid arthritis (RA) pathology. Current disease-modifying antirheumatic agents (DMARDs) operate through systemic immunosuppression. FLS-targeted approaches could potentially be combined with DMARDs to improve control of RA without increasing immunosuppression. Here, we...

Cite
Svensson MND, Zoccheddu M, Yang S, et al. Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal. Sci Adv. 2020;6(26):eaba4353doi: 10.1126/sciadv.aba4353.
Svensson, M. N. D., Zoccheddu, M., Yang, S., Nygaard, G., Secchi, C., Doody, K. M., Slowikowski, K., Mizoguchi, F., Humby, F., Hands, R., Santelli, E., Sacchetti, C., Wakabayashi, K., Wu, D. J., Barback, C., Ai, R., Wang, W., Sims, G. P., Mydel, P., Kasama, T., Boyle, D. L., Galimi, F., Vera, D., Tremblay, M. L., Raychaudhuri, S., Brenner, M. B., Firestein, G. S., Pitzalis, C., Ekwall, A. H., Stanford, S. M., & Bottini, N. (2020). Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal. Science advances, 6(26), eaba4353. https://doi.org/10.1126/sciadv.aba4353
Svensson, Mattias N D, et al. "Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal." Science advances vol. 6,26 (2020): eaba4353. doi: https://doi.org/10.1126/sciadv.aba4353
Svensson MND, Zoccheddu M, Yang S, Nygaard G, Secchi C, Doody KM, Slowikowski K, Mizoguchi F, Humby F, Hands R, Santelli E, Sacchetti C, Wakabayashi K, Wu DJ, Barback C, Ai R, Wang W, Sims GP, Mydel P, Kasama T, Boyle DL, Galimi F, Vera D, Tremblay ML, Raychaudhuri S, Brenner MB, Firestein GS, Pitzalis C, Ekwall AH, Stanford SM, Bottini N. Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal. Sci Adv. 2020 Jun 26;6(26):eaba4353. doi: 10.1126/sciadv.aba4353. eCollection 2020 Jun. PMID: 32637608; PMCID: PMC7319753.
Copy Download .nbib Format: NLM
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.

Annals of the rheumatic diseases

Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Rodrigues A, Raffeiner B, Duarte C, Hachulla E, Veillard E, Strakova E, Burmester GR, Yardımcı GK, Gomez-Puerta JA, Zepa J, Kearsley-Fleet L, Trefond L, Cunha M, Mosca M, Cornalba M, Soubrier M, Roux N, Brocq O, Durez P, Conway R, Goulenok T, Bijlsma JW, McInnes IB, Mariette X.
PMID: 34972811
Ann Rheum Dis. 2021 Dec 31; doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.

OBJECTIVES: To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).METHODS: Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we...

Cite
Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221490.
Machado, P. M., Lawson-Tovey, S., Strangfeld, A., Mateus, E. F., Hyrich, K. L., Gossec, L., Carmona, L., Rodrigues, A., Raffeiner, B., Duarte, C., Hachulla, E., Veillard, E., Strakova, E., Burmester, G. R., Yardımcı, G. K., Gomez-Puerta, J. A., Zepa, J., Kearsley-Fleet, L., Trefond, L., Cunha, M., Mosca, M., Cornalba, M., Soubrier, M., Roux, N., Brocq, O., Durez, P., Conway, R., Goulenok, T., Bijlsma, J. W., McInnes, I. B., & Mariette, X. (2021). Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221490
Machado, Pedro M, et al. "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221490
Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Rodrigues A, Raffeiner B, Duarte C, Hachulla E, Veillard E, Strakova E, Burmester GR, Yardımcı GK, Gomez-Puerta JA, Zepa J, Kearsley-Fleet L, Trefond L, Cunha M, Mosca M, Cornalba M, Soubrier M, Roux N, Brocq O, Durez P, Conway R, Goulenok T, Bijlsma JW, McInnes IB, Mariette X. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021 Dec 31; doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31. PMID: 34972811; PMCID: PMC8720639.
Copy Download .nbib Format: NLM
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Annals of the rheumatic diseases

Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR.
PMID: 33452004
Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15.

OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure.METHODS: This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-daily oral...

Cite
Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219213.
Westhovens, R., Rigby, W. F. C., van der Heijde, D., Ching, D. W. T., Stohl, W., Kay, J., Chopra, A., Bartok, B., Matzkies, F., Yin, Z., Guo, Y., Tasset, C., Sundy, J. S., Jahreis, A., Mozaffarian, N., Messina, O. D., Landewé, R. B., Atsumi, T., & Burmester, G. R. (2021). Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens, René, et al. "Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15. PMID: 33452004; PMCID: PMC8142453.
Copy Download .nbib Format: NLM
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.

Annals of the rheumatic diseases

Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE.
PMID: 34740884
Ann Rheum Dis. 2021 Nov 05; doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 05.

OBJECTIVE: To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis.METHODS: Data were integrated from seven trials (NCT01668641, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700, NCT03025308). Results are from placebo (PBO)-controlled (through...

Cite
Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221051.
Winthrop, K. L., Tanaka, Y., Takeuchi, T., Kivitz, A., Matzkies, F., Genovese, M. C., Jiang, D., Chen, K., Bartok, B., Jahreis, A., Besuyen, R., Burmester, G. R., & Gottenberg, J. E. (2021). Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221051
Winthrop, Kevin L, et al. "Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221051
Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2021 Nov 05; doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 05. PMID: 34740884.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 120 entries